Business Description
Lakefront Biotherapeutics NV
NAICS : 541714
SIC : 2834
ISIN : BE0003818359
Share Class Description:
XAMS:LKFT: Ordinary SharesTotal Employee Number:
452Compare
Compare
Traded in other countries / regions
LKFT.NetherlandsLKFT.USA0JXZ.UKGXE.GermanyLKFT.AustriaLKFT34.BrazilLKFT.BelgiumGLPGN.Mexico IPO Date
2005-05-06Description
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 352.02 | |||||
Equity-to-Asset | 0.97 | |||||
Debt-to-EBITDA | 0.01 | |||||
Interest Coverage | 2663.37 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 13.11 | |||||
Beneish M-Score | 1.26 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 66.3 | |||||
3-Year EBITDA Growth Rate | 352 | |||||
3-Year FCF Growth Rate | 20.5 | |||||
3-Year Book Growth Rate | 8.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -42.61 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 61.91 | |||||
9-Day RSI | 58.76 | |||||
14-Day RSI | 55.83 | |||||
3-1 Month Momentum % | 2.77 | |||||
6-1 Month Momentum % | -13.49 | |||||
12-1 Month Momentum % | -10.06 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 32.84 | |||||
Quick Ratio | 32.72 | |||||
Cash Ratio | 31.85 | |||||
Days Inventory | 304.99 | |||||
Days Sales Outstanding | 11.48 | |||||
Days Payable | 1239.21 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 97.45 | |||||
Operating Margin % | 61.57 | |||||
Net Margin % | 60.23 | |||||
EBITDA Margin % | 58.45 | |||||
FCF Margin % | -23.37 | |||||
OCF Margin % | -22.91 | |||||
ROE % | 20.1 | |||||
ROA % | 17.09 | |||||
ROIC % | 93.7 | |||||
3-Year ROIIC % | -146.22 | |||||
ROC (Joel Greenblatt) % | 643.63 | |||||
ROCE % | 17.69 | |||||
Years of Profitability over Past 10-Year | 5 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 2.79 | |||||
Forward PE Ratio | 156.25 | |||||
PE Ratio without NRI | 2.51 | |||||
PS Ratio | 1.68 | |||||
PB Ratio | 0.51 | |||||
Price-to-Tangible-Book | 0.66 | |||||
EV-to-EBIT | -1 | |||||
EV-to-Forward-EBIT | 40.81 | |||||
EV-to-EBITDA | -1 | |||||
EV-to-Forward-EBITDA | 35.19 | |||||
EV-to-Revenue | -0.58 | |||||
EV-to-Forward-Revenue | 1.25 | |||||
EV-to-FCF | 2.5 | |||||
Price-to-GF-Value | 0.25 | |||||
Price-to-Median-PS-Value | 0.13 | |||||
Price-to-Graham-Number | 0.27 | |||||
| Price-to-Net-Current-Asset-Value | 0.75 | |||||
| Price-to-Net-Cash | 0.77 | |||||
Earnings Yield (Greenblatt) % | -100 | |||||
FCF Yield % | -13.99 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lakefront Biotherapeutics NV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 990.574 | ||
| EPS (TTM) (€) | 9.05 | ||
| Beta | 0.2496 | ||
| 3-Year Sharpe Ratio | -0.53 | ||
| 3-Year Sortino Ratio | -0.72 | ||
| Volatility % | 20.79 | ||
| 14-Day RSI | 55.83 | ||
| 14-Day ATR (€) | 0.804529 | ||
| 20-Day SMA (€) | 24.098 | ||
| 12-1 Month Momentum % | -10.06 | ||
| 52-Week Range (€) | 22.32 - 32.74 | ||
| Shares Outstanding (Mil) | 65.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lakefront Biotherapeutics NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lakefront Biotherapeutics NV Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-24 08:00 | In 182 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-24 | In 181 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-13 | In 78 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 77 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-11 | 23.44 (+0.17%) | ||
| Second quarter earnings results for 2026 | 2026-08-10 | 23.34 (+3.18%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 14:00 | 24.62 (+0.16%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 24.32 (+0.50%) | ||
| General meeting for 2026 | 2026-04-28 14:00 | 24.42 (+0.33%) | ||
| Annual report for 2025 | 2026-03-26 | 26.58 (+0.38%) |
Show
Entries
Lakefront Biotherapeutics NV Frequently Asked Questions
What is Lakefront Biotherapeutics NV(XAMS:LKFT)'s stock price today?
The current price of XAMS:LKFT is €25.28. The 52 week high of XAMS:LKFT is €32.74 and 52 week low is €22.32.
When is next earnings date of Lakefront Biotherapeutics NV(XAMS:LKFT)?
The next earnings date of Lakefront Biotherapeutics NV(XAMS:LKFT) is 2026-11-12.
Does Lakefront Biotherapeutics NV(XAMS:LKFT) pay dividends? If so, how much?
Lakefront Biotherapeutics NV(XAMS:LKFT) does not pay dividend.
Press Release
Articles on Lakefront Biotherapeutics NV
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers